CD34 and Alzheimer disease: Studies have shown that brain endothelial damage increases AD pathogenesis in the brain in certain genotype carriers [6], therefore, we hypothesized that peripheral circulating CD34+CD133+ EPCs may reduce AD risk in particular genotypes.